Logo image of GLMD

GALMED PHARMACEUTICALS LTD (GLMD) Stock News

NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD

1.39  -0.02 (-1.42%)

GLMD Latest News, Press Relases and Analysis

News Image
17 days ago - Chartmill

What's going on in today's pre-market session

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Mentions: DGLY FARO MRIN TCMD ...

News Image
17 days ago - Stocktwits

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

News Image
17 days ago - Galmed Pharmaceuticals Ltd.

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic...

News Image
25 days ago - Galmed Pharmaceuticals Ltd.

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases...

News Image
a month ago - Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on...

News Image
a month ago - Galmed Pharmaceuticals Ltd.

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and...

News Image
a month ago - Galmed Pharmaceuticals Ltd.

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical...

News Image
2 months ago - Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver,...

News Image
2 months ago - Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver,...

News Image
8 months ago - Galmed Pharmaceuticals Ltd.

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory...

News Image
a year ago - InvestorPlace

GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024

Galmed Pharmaceuticals just reported results for the first quarter of 2024.

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!

Mentions: MRIN MSFT ICCT NA ...

News Image
a year ago - InvestorPlace

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Explore three penny stocks primed for significant growth, backed by Strong Buy ratings from Wall Street. Play it high-risk.

Mentions: SLNA TCON

News Image
a year ago - InvestorPlace

GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023

GLMD stock results show that Galmed Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
a year ago - Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...